Durvalumab plus etoposide-carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E).
CLINICAL TRIAL REGISTRATION jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).
3 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
CLINICAL TRIAL REGISTRATION jRCT2031230456 (https://jrct.mhlw.go.jp/latest-detail/jRCT2031230456).
Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal because most patients are diagnosed after curative intervention is no longer feasible and resistance to systemic therapy is common. Intraductal papillary mucinous neoplasms (IPMNs) are important PDAC precursor lesions, but serum biomarkers for early PDAC d...
KRAS G12D is a prevalent oncogenic driver in PDAC, which has a high unmet need due to few effective targeted therapies. Setidegrasib, a novel KRAS G12D-targeted protein degrader, eliminates the oncogenic driver to suppress downstream signaling and induce tumor cell death. Early clinical activity was reported in a...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.